SocGen Uses Lyxor To Push OTCs In Asia

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

SocGen Uses Lyxor To Push OTCs In Asia

Amid dwindling demand for over-the-counter equity derivatives, Société Générale is touting its Lyxor Asset Management managed account products platform to institutional investors in Hong Kong to lure them towards more sophisticated hedging strategies.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • 4 capital markets databases
  • Daily newsletters across markets and asset classes
  • 2 weekly podcasts
Gift this article